Pharmacosmos' Monoferric 1000 mg IV Receives Health Canada Marketing Approval
Shots:
- Monoferric is being approved for anaemic adult patients intolerant or unresponsive to iron oral therapy with an expection to reach market by Nov 2018
- In 2015- Pharmacosmos signed Canada commercialization rights of Monoferric to Pfizer Canada
- Monoferric IV has a novel matrix structure of linear isomaltoside chains interspersed with Fe3+ and already being marketed in >30 countries worldwide
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
